Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Moreno

Showing results (261-270 of 548) with videos related to

Pageof 55
Sort By:
Cancer Medicine|July 6, 2024
Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumorsAgostina Stradella, Melissa Johnson, Sanjay Goel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2019
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLCTodd M Bauer, Benjamin Besse, Alex Martinez-Marti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2021
Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynxCaroline Hoffmann, Valentin Calugaru, Edith Borcoman, et al.
Molecular Cancer Therapeutics|April 3, 2016
Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR TherapiesDaniel Azuara, Cristina Santos, Adriana Lopez-Doriga, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitorsMalaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo, et al.
Human Mutation|November 15, 2013
ICO amplicon NGS data analysis: a Web tool for variant detection in common high-risk hereditary cancer genes analyzed by amplicon GS Junior next-generation sequencingAdriana Lopez-Doriga, Lídia Feliubadaló, Mireia Menéndez, et al.
Neuro-Oncology|December 1, 2022
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" studyVictor Moreno, Juan Manuel Sepúlveda, David A Reardon, et al.
Investigational New Drugs|August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational studyRebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical EfficacyJennifer R Diamond, Valentina Boni, Emerson Lim, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumorsMichele Maio, Victor Moreno, Juan Martin-Liberal, et al.
Pageof 55

Showing results (261-270 of 548) with videos related to

Sort By:
Pageof 55
Cancer Medicine|July 6, 2024
Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumorsAgostina Stradella, Melissa Johnson, Sanjay Goel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2019
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLCTodd M Bauer, Benjamin Besse, Alex Martinez-Marti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2021
Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynxCaroline Hoffmann, Valentin Calugaru, Edith Borcoman, et al.
Molecular Cancer Therapeutics|April 3, 2016
Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR TherapiesDaniel Azuara, Cristina Santos, Adriana Lopez-Doriga, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitorsMalaka Ameratunga, Maxime Chénard-Poirier, Irene Moreno Candilejo, et al.
Human Mutation|November 15, 2013
ICO amplicon NGS data analysis: a Web tool for variant detection in common high-risk hereditary cancer genes analyzed by amplicon GS Junior next-generation sequencingAdriana Lopez-Doriga, Lídia Feliubadaló, Mireia Menéndez, et al.
Neuro-Oncology|December 1, 2022
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" studyVictor Moreno, Juan Manuel Sepúlveda, David A Reardon, et al.
Investigational New Drugs|August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational studyRebecca Kristeleit, Alexandra Leary, Jean Pierre Delord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical EfficacyJennifer R Diamond, Valentina Boni, Emerson Lim, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumorsMichele Maio, Victor Moreno, Juan Martin-Liberal, et al.
Pageof 55